| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20045750 | HPV | ENSG00000162434.14 | protein_coding | JAK1 | Yes | Yes | 3716 | P23458 Q6P669 |
| TVIS44024604 | HTLV-1 | ENSG00000162434.14 | protein_coding | JAK1 | Yes | Yes | 3716 | P23458 Q6P669 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | JAK1 |
|---|---|
| DrugBank ID | DB08877 |
| Drug Name | Ruxolitinib |
| Target ID | BE0004145 |
| UniProt ID | P23458 |
| Regulation Type | inhibitor |
| PubMed IDs | 23514013; 23061804; 21919691 |
| Citations | Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21.@@Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000.@@Ostojic A, Vrhovac R, Verstovsek S: Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011 Sep;7(9):1035-43. doi: 10.2217/fon.11.81. |
| Groups | Approved |
| Direct Classification | Pyrrolo[2,3-d]pyrimidines |
| SMILES | N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1 |
| Pathways | |
| PharmGKB | PA166123386 |
| ChEMBL | CHEMBL1789941 |
